SenzaGen Newsletter December 2024
As 2024 ends, we’re proud to share how our innovative GARD? method is addressing key challenges in skin sensitization testing. In Q4, we’ve focused on filling data gaps in areas like Medical Devices, Safe Dose Levels, and Complex Mixtures—driving the shift to reliable, human-relevant solutions: